Clinical trial
Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK…
NCT00263653 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00263653 |
|---|---|
| Title | Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197 |
| Official title | Study to Evaluate the Safety, Reactogenicity & Immunogenicity of a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™, vs Hib-MenC or Priorix™ Only, in Toddlers (13-14 m) Primed With 3 Doses of Hib (as Part of a DTPa -Containing Vaccine) & MenC-CRM197 Conjugate Vaccines. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Haemophilus Influenzae Type b, Neisseria Meningitidis |
| Intervention type | Biological |
| Interventions | Haemophilus influenzae type b- and meningococcal (vaccine) |
| Enrollment | 297 |
| Start date | Mar 1, 2005 |
| Primary completion | Mar 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Dec 9, 2005 |
| Last update posted | Sep 21, 2016 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: